8-K: Evolus Achieves First Ever Quarterly Profitability, Raises Full Year Revenue Guidance

Evolus reports its first profitable quarter with a 36% revenue increase year-over-year and raises its full-year revenue guidance to $260-$270 million.

Summary

• Evolus reported its financial results for the second quarter of 2024, achieving its first ever quarter of profitability with a non-GAAP operating income of $1.1 million.
• Total net revenue for the quarter was $66.9 million, a 36% increase compared to $49.3 million in the same quarter of 2023.
• The company has raised its full-year 2024 net revenue guidance to between $260 million and $270 million, representing a 34% year-over-year growth at the top end.
• Evolus added 770 new customer accounts in the quarter, bringing the total to approximately 14,000 since launch.
• The customer reorder rate was approximately 70%.
• The Evolus Rewards program grew to over 900,000 members with nearly 190,000 redemptions in the quarter.
• The company submitted a Premarket Approval (PMA) application to the FDA for its Evolysse Lift and Evolysse Smooth dermal fillers, with approval and launch expected in the second half of 2025.
• Evolus also launched Nuceiva in Spain and expects to launch in Australia in Q3 2024.
• The company anticipates regulatory approvals for the remaining Estyme dermal filler products in Europe in late 2024.
• Evolus projects its total net revenue to reach at least $700 million by 2028.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the company achieving its first profitable quarter, strong revenue growth, and raised full-year guidance. The company is also making progress on product development and global expansion, which further contributes to the positive outlook.

Positives

• Evolus achieved its first ever quarter of profitability, demonstrating strong financial performance.
• The company experienced a significant 36% increase in revenue compared to the same quarter last year.
• Evolus has raised its full-year revenue guidance, indicating confidence in future growth.
• The company is expanding its customer base and seeing strong customer loyalty with a 70% reorder rate.
• The Evolus Rewards program is growing rapidly, indicating strong consumer engagement.
• The company is making progress in expanding its product portfolio with the submission of the PMA application for its dermal fillers.
• Evolus is expanding its global footprint with launches in new markets.
• The company is on track to achieve its long-term revenue goal of $700 million by 2028.

Negatives

• The company reported a GAAP operating loss of $7.7 million for the quarter, although this is an improvement from the previous quarter.
• Cash and cash equivalents decreased slightly from $97.0 million to $93.7 million during the quarter.
• Operating expenses for the second quarter of 2024 were $74.6 million, compared to $68.3 million in the first quarter of 2024.

Risks

• The company's future performance is subject to risks and uncertainties, including the ability to comply with the Medytox Settlement Agreements.
• There are risks associated with funding future operations and obtaining financing.
• Unfavorable global economic conditions could impact consumer spending and demand for the company's products.
• The company faces competition and market dynamics that could affect its performance.
• There are risks associated with successfully launching and commercializing new products in new markets.
• The company's ability to maintain regulatory approvals for existing products and obtain approvals for new products is not guaranteed.
• The company relies on third parties for regulatory approvals and product development.

Future Outlook

Evolus expects to achieve positive non-GAAP operating income on a consolidated basis for the fourth quarter of 2024 and for the full year 2025. The company also projects its total net revenue can reach at least $700 million by 2028.

Management Comments

• David Moatazedi, President and Chief Executive Officer, stated that the company is thrilled to have achieved quarterly profitability for the first time, driven by record revenue.
• Moatazedi also noted that the company is raising its full-year 2024 net revenue guidance due to record quarterly revenue and all-time highs across key performance indicators.
• Moatazedi highlighted the continued strength of Jeuveau, the expansion of the global footprint, and the progress made in expanding the portfolio with the recent submission of the PMA for the Evolysse dermal fillers.

Industry Context

This announcement reflects a positive trend in the aesthetic market, with Evolus demonstrating strong growth and profitability. The company's focus on expanding its product portfolio and global reach aligns with industry trends of diversification and international expansion. The submission of the PMA for dermal fillers positions Evolus to compete more broadly in the aesthetics market.

Comparison to Industry Standards

• Evolus's 36% year-over-year revenue growth in Q2 2024 is strong compared to some of its competitors in the aesthetics market, such as Allergan (now part of AbbVie) and Galderma, although direct comparisons are difficult due to varying product portfolios and reporting periods.
• The achievement of non-GAAP operating profitability is a significant milestone for Evolus, as many companies in the early stages of commercialization often struggle to achieve profitability.
• The company's focus on expanding its product portfolio with the Evolysse dermal fillers is similar to strategies employed by larger players in the industry, such as Allergan and Merz, who offer a range of neurotoxins and fillers.
• Evolus's customer reorder rate of 70% indicates strong customer loyalty, which is a key metric for success in the aesthetics market, and is comparable to industry leaders.
• The company's expansion into new markets, such as Spain and Australia, is consistent with the global growth strategies of other aesthetic companies.

Stakeholder Impact

• Shareholders will likely react positively to the news of the company's first profitable quarter and raised revenue guidance.
• Employees may be motivated by the company's strong performance and future growth prospects.
• Customers will benefit from the expansion of the company's product portfolio and global reach.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• Evolus will continue to expand into additional countries with Nuceiva.
• The company expects regulatory approvals for the remaining Estyme dermal filler products in Europe in late 2024.
• Evolus anticipates the approval and launch of Evolysse Lift and Evolysse Smooth fillers in the second half of 2025.
• The company will continue to work towards achieving its 2028 revenue goal of at least $700 million.

Key Dates

Keywords

Evolus, Jeuveau, Nuceiva, Evolysse, Estyme, dermal fillers, neurotoxin, aesthetics, revenue, profitability, FDA, PMA, financial results